HDAC6 and gastric neoplasm: This has resulted in several anti-cancer successes including Food and Drug Administration (FDA)-approved 26S proteosome inhibitors such as bortezomib, carfilzomib, and ixazomib; the Histone Deacetylase 6 (HDAC6) inhibitor panobinostat; and pimitespib (TAS-116), an HSP90 inhibitor approved for use against stomach cancer in Japan [3].